Alteplase IS Used in Acute MI—It's a Standard Treatment Option
Alteplase (tissue plasminogen activator) is absolutely indicated and widely used in acute ST-elevation myocardial infarction (STEMI) when primary percutaneous coronary intervention (PCI) cannot be achieved rapidly. The premise of your question appears to be based on a misconception—alteplase is not contraindicated in acute MI; rather, it's a guideline-recommended fibrinolytic therapy for appropriate patients 1, 2.
When Alteplase Should Be Used in Acute MI
Primary PCI remains the gold standard reperfusion strategy, but fibrinolytic therapy with alteplase is indicated when:
- Time to PCI exceeds acceptable delays (generally when door-to-balloon time cannot be achieved within 120 minutes) 1, 2
- Patient presents within 12 hours of symptom onset, particularly those presenting early with large anterior infarctions and low bleeding risk 1, 2
- Geographic or logistical barriers prevent timely access to a PCI-capable facility
The 2025 ACC/AHA guidelines explicitly support fibrinolytic therapy in these scenarios, with time-dependent mortality and morbidity reduction well-established in the first 12 hours after symptom onset 1, 2.
Dosing and Administration
The standard alteplase regimen for STEMI is a 90-minute weight-based infusion 2:
- 15 mg IV bolus
- 50 mg IV over 30 minutes (or 0.75 mg/kg, not to exceed 50 mg)
- 35 mg IV over 60 minutes (or 0.5 mg/kg, not to exceed 35 mg)
- Total maximum dose: 100 mg
This "accelerated infusion" protocol has been shown superior to other dosing strategies and remains the preferred regimen 3.
When Alteplase Should NOT Be Used
Absolute Contraindications 1, 2:
- Any prior intracranial hemorrhage
- Known structural cerebrovascular lesion (AV malformation)
- Known malignant intracranial neoplasm
- Ischemic stroke within 3 months (except acute ischemic stroke within 4.5 hours)
- Suspected aortic dissection
- Active bleeding or bleeding diathesis
- Significant closed-head or facial trauma within 3 months
- Intracranial/intraspinal surgery within 2 months
- Severe uncontrolled hypertension (SBP >180 or DBP >110 mm Hg unresponsive to therapy)
Relative Contraindications 1, 2:
- Chronic severe poorly controlled hypertension
- Prior ischemic stroke >3 months ago
- Traumatic or prolonged CPR (>10 minutes)
- Major surgery within 3 weeks
- Recent internal bleeding (2-4 weeks)
- Pregnancy
- Active peptic ulcer
- Oral anticoagulant therapy
Clinical Scenarios Where Alteplase Should Be Avoided:
ST-segment depression without true posterior MI: Fibrinolytic therapy should NOT be administered to patients presenting with only ST-segment depression (Class 3: Harm recommendation), as this increases risk of hemorrhagic stroke and major bleeding without benefit 2.
Presentation >12 hours after symptom onset: The benefit of fibrinolytic therapy beyond 12 hours is not established 1, 2. Exception: Consider in symptomatic patients with large area of myocardium at risk or hemodynamic instability when PCI unavailable.
Why Tenecteplase May Be Preferred Over Alteplase
Tenecteplase has emerged as the preferred fibrin-specific agent because it offers equivalent 30-day mortality to alteplase but with reduced noncerebral bleeding and the convenience of single-bolus administration versus 90-minute infusion 1, 2. This represents an evolution in practice, though alteplase remains effective and appropriate.
Critical Post-Fibrinolytic Management
All patients receiving alteplase must be transferred to a PCI-capable hospital for routine coronary angiography 1. This is non-negotiable. Signs of failed reperfusion include:
- Lack of improvement in ischemic symptoms
- Persistent ST-segment elevation (<50% resolution in anterior leads or <70% in inferior leads)
- Hemodynamic or electrical instability
These patients require immediate rescue PCI 1.
Common Pitfalls to Avoid
- Delaying fibrinolysis while waiting for PCI: If transfer time to PCI-capable facility exceeds 120 minutes, initiate fibrinolytic therapy immediately—time is myocardium
- Using alteplase in isolated ST-depression: This causes harm without benefit 2
- Failing to transfer post-fibrinolysis: Even successful fibrinolysis requires angiography within 2-24 hours
- Ignoring relative contraindications in high-risk patients: Weigh bleeding risk carefully, particularly in elderly patients with comorbidities
The evidence is clear: alteplase is not avoided in acute MI—it's a lifesaving intervention when used appropriately in the right clinical context with proper patient selection.